Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion Effet de l'aflibercept sur œdème maculaire persistant secondaire à une occlusion de la veine centrale de la rétine

KAYA F., Kocak I., AYDIN A., Baybora H., Koc H., Karabela Y.

Journal Francais d'Ophtalmologie, vol.41, no.9, pp.809-813, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 9
  • Publication Date: 2018
  • Doi Number: 10.1016/j.jfo.2018.01.024
  • Journal Name: Journal Francais d'Ophtalmologie
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.809-813
  • Keywords: Ranibizumab, Aflibercept, Central retinal vein occlusion, Persistent macular edema
  • Istanbul Medipol University Affiliated: Yes


Purpose: To evaluate the efficacy of switching treatment from intravitreal ranibizumab to intravitreal aflibercept on the treatment of refractory macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this retrospective study; 12 eyes with refractory macular edema secondary to CRVO after multiple monthly repeated intravitreal 0.5 mg/0.05 mL ranibizumab injections prior to switching therapy to intravitreal 2 mg/0.05 mL aflibercept, between March 2012 and April 2016 were reviewed. The follow-up time was 12 months. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), central retinal volume (CRV) and injection interval between baseline and month 1, 3, 6 and 12 after switching therapy to aflibercept were reviewed and evaluated. Results: Mean baseline CRT decreased from 516 ± 101 mic. to 252 ± 114 mic. at month 12 (P = 0.008). Mean baseline CRV decreased from 8.74 ± 2.13 mm3 to 6.82 ± 1.64 mm3 at month 12 (P = 0.005). Baseline BCVA improved from 0.73 ± 0.21 to 0.53 ± 0.17 logMAR at month 12 (P = 0.004). Mean BCVA gain was two logMar lines (10 letters) at month 12. After switching therapy to aflibercept; the mean injection interval increased significantly from 1.34 months at baseline to 1.86 months at month 12, by an increase of 0.52 months (P = 0.02). Conclusion: Intravitreal aflibercept is evaluated to be presenting significant visual and anatomical improvements in patients with persistent macular edema due to CRVO despite previous intravitreal ranibizumab.